Biogen Inc (BIIB)

BIIB (NASDAQ:Drugs) EQUITY
$252.20
pos +2.21
+0.88%
Today's Range: 249.28 - 257.37 | BIIB Avg Daily Volume: 1,864,800
Last Update: 02/10/16 - 3:59 PM EST
Volume: 1,745,217
YTD Performance: -18.14%
Open: $253.40
Previous Close: $249.99
52 Week Range: $243.85 - $480.18
Oustanding Shares: 218,672,717
Market Cap: 54,836,557,242
6-Month Chart
TheStreet Ratings Grade for BIIB
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 10 12 12 11
Moderate Buy 2 2 2 2
Hold 8 7 7 7
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.88 1.74 1.74 1.77
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 16.39
Price Earnings Comparisons:
BIIB Sector Avg. S&P 500
16.39 16.30 26.96
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-15.09% -37.81% 52.50%
GROWTH 12 Mo 3 Yr CAGR
Revenue 46.50 0.95 0.25
Net Income 22.20 1.60 0.37
EPS 24.00 1.65 0.38
Earnings for BIIB:
EBITDA 4.06B
Revenue 9.42B
Average Earnings Estimates
Qtr (03/16) Qtr (06/16) FY (12/16) FY (12/17)
Average Estimate $4.45 $4.60 $18.62 $20.19
Number of Analysts 20 20 21 21
High Estimate $4.80 $4.88 $19.45 $22.07
Low Estimate $4.00 $4.27 $18.02 $18.61
Prior Year $3.82 $4.22 $17.01 $18.62
Growth Rate (Year over Year) 16.43% 9.02% 9.47% 8.43%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
By

Jim Cramer

 | Feb 1, 2016 | 10:35 AM EST

Jim Cramer says healthcare companies will be in the spotlight this week and investors should take a long term view of the sector if the stocks selloff.

By

Robert Lang

 | Jan 28, 2016 | 12:00 PM EST

Is the biotech company's stock on its way higher?

By

Robert Lang

 | Jan 28, 2016 | 9:00 AM EST

The stock may be on its way higher.

By

Chris Laudani

 | Jan 26, 2016 | 11:00 AM EST

BIIB needs to announce some top-line suprises when it reports on Wednesday to spark investor enthusiasm.

By

Jim Cramer

 | Dec 17, 2015 | 12:32 PM EST

General Mills (GIS) is a still a stock to hold for the long term, even as the company missed on earnings due to a slump in cereal sales, says Cramer.

By

Robert Lang

 | Dec 11, 2015 | 10:00 AM EST

BIIB's action since late November has been constructive. 

By

Ed Ponsi

 | Dec 9, 2015 | 12:30 PM EST

I chose stocks that I believe present the best investment opportunity right now.

By

Ed Ponsi

 | Dec 9, 2015 | 9:00 AM EST

I picked the stocks that I believe present the best investment opportunity right now.

By

Jim Cramer

 | Dec 8, 2015 | 4:06 PM EST

There are more bad cards in the deck than good ones right now, but that's no reason to quit the game.

By

Jim Cramer and Jack Mohr

 | Dec 4, 2015 | 8:00 AM EST

Let's break it down into several components.

Juniper appears headed for a re test of major support near its 2015 low. With today'...

$550 million to buy.

Spooking the markets now.

SPY $185.75
IWM $96.24

REAL MONEY PRO'S BEST IDEAS

News Breaks

Powered by
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.